IL33 and type 2 diabetes mellitus: There are various mechanisms by which glucose-lowering medications confer their metabolic effects; in addition to these, we speculate that these medications may also target and restore the dynamics and biological functions of IL-33/ST2 in the adipose tissue of individuals with T2D.